Investigational Drug Information for ACT-541468
✉ Email this page to a colleague
What is the development status for investigational drug ACT-541468?
ACT-541468 is an investigational drug.
There have been 22 clinical trials for ACT-541468.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 29th 2018.
The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Disease, and Sleep Apnea, Obstructive. The leading clinical trial sponsors are Idorsia Pharmaceuticals Ltd., Actelion, and University Hospital, Basel, Switzerland.
There are four US patents protecting this investigational drug and eighty-seven international patents.
Summary for ACT-541468
| US Patents | 4 |
| International Patents | 87 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2018-05-29) |
| Vendors | 27 |
Recent Clinical Trials for ACT-541468
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep | Idorsia Pharmaceuticals Ltd. | Phase 1 |
| Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects | Idorsia Pharmaceuticals Ltd. | Phase 1 |
| A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects | Idorsia Pharmaceuticals Ltd. | Phase 1 |
Clinical Trial Summary for ACT-541468
Top disease conditions for ACT-541468
Top clinical trial sponsors for ACT-541468
US Patents for ACT-541468
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ACT-541468 | ⤷ Subscribe | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-meth- oxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) | ⤷ Subscribe |
| ACT-541468 | ⤷ Subscribe | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) | ⤷ Subscribe |
| ACT-541468 | ⤷ Subscribe | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) | ⤷ Subscribe |
| ACT-541468 | ⤷ Subscribe | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-- yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ACT-541468
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ACT-541468 | Australia | AU2014358743 | 2033-12-03 | ⤷ Subscribe |
| ACT-541468 | Brazil | BR112016012625 | 2033-12-03 | ⤷ Subscribe |
| ACT-541468 | Canada | CA2929720 | 2033-12-03 | ⤷ Subscribe |
| ACT-541468 | Chile | CL2016001348 | 2033-12-03 | ⤷ Subscribe |
| ACT-541468 | China | CN105793258 | 2033-12-03 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
